News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
198,559 Results
Type
Article (19610)
Company Profile (105)
Press Release (178844)
Section
Business (63952)
Career Advice (823)
Deals (9064)
Drug Delivery (72)
Drug Development (18814)
Employer Resources (137)
FDA (3347)
Job Trends (6009)
News (95352)
Policy (7069)
Tag
Academia (1491)
Alliances (17344)
Alzheimer's disease (534)
Antibody-drug conjugate (ADC) (54)
Approvals (3341)
Artificial intelligence (113)
Best Places to Work (4925)
Biotechnology (65)
Breast cancer (79)
Cancer (532)
Career advice (723)
Cell therapy (133)
Clinical research (14202)
Collaboration (325)
Compensation (63)
COVID-19 (959)
C-suite (93)
Data (503)
Diabetes (60)
Diagnostics (2341)
Earnings (14532)
Employer resources (117)
Events (29518)
Executive appointments (315)
FDA (3599)
Funding (292)
Gene therapy (91)
GLP-1 (293)
Government (1313)
Healthcare (4943)
Infectious disease (1008)
Inflammatory bowel disease (54)
Interviews (115)
IPO (3646)
Job creations (1303)
Job search strategy (637)
Layoffs (158)
Legal (1185)
Lung cancer (83)
Manufacturing (106)
Medical device (2608)
Medtech (2612)
Mergers & acquisitions (5604)
Metabolic disorders (188)
Neuroscience (704)
NextGen: Class of 2025 (2110)
Non-profit (1686)
Northern California (679)
Obesity (120)
Opinion (104)
People (26954)
Phase I (4184)
Phase II (5887)
Phase III (5660)
Pipeline (209)
Postmarket research (559)
Preclinical (2375)
Press Release (61)
Radiopharmaceuticals (62)
Rare diseases (106)
Real estate (2515)
Recruiting (53)
Regulatory (5074)
Research institute (1261)
Resumes & cover letters (106)
Series A (61)
Southern California (473)
Startups (2002)
United States (5828)
Vaccines (180)
Weight loss (89)
Date
Today (44)
Last 7 days (223)
Last 30 days (852)
Last 365 days (11031)
2025 (1783)
2024 (11453)
2023 (13016)
2022 (15610)
2021 (17741)
2020 (16355)
2019 (15101)
2018 (10899)
2017 (10361)
2016 (10242)
2015 (10945)
2014 (8075)
2013 (7008)
2012 (7422)
2011 (7598)
2010 (7058)
Location
Africa (328)
Arizona (60)
Asia (11212)
Australia (1958)
California (1431)
Canada (541)
China (117)
Colorado (83)
Connecticut (55)
Delaware (64)
Europe (28800)
Florida (214)
Illinois (118)
Indiana (127)
Japan (56)
Maryland (176)
Massachusetts (1211)
Michigan (84)
Minnesota (105)
New Jersey (468)
New York (558)
North Carolina (293)
Northern California (679)
Ohio (59)
Pennsylvania (239)
South America (394)
Southern California (473)
Texas (185)
Washington State (117)
198,559 Results for "sage science".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Legal
Sage Sues Partner Biogen After Unsolicited Takeover Offer
Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital Markets.
January 21, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
January 27, 2025
·
1 min read
·
Annalee Armstrong
Neuroscience
Biogen Submits Offer to Buy Embattled Partner Sage
Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of Sage Therapeutics have fallen by more than 90%.
January 13, 2025
·
3 min read
·
Heather McKenzie
Podcast
RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More
Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees more action with new company launches, IPOs and fresh data; and experts get ready for an important era in the Duchenne muscular dystrophy space.
January 29, 2025
·
1 min read
·
Heather McKenzie
Business
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference. Meanwhile, Biogen proposes to acquire struggling neuro partner Sage, and obesity dominates discussions as Pfizer goes “all in.”
January 15, 2025
·
1 min read
·
Heather McKenzie
Editorial
Embattled Sage Dealt Deeper Blow With Huntington’s Failure
Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts to question the biotech’s future profitability.
November 25, 2024
·
4 min read
·
Heather McKenzie
Huntington’s disease
Sage Scraps Huntington’s Hopeful After Disappointing Phase II Data
After previously failing studies in Parkinson’s and Alzheimer’s, dalzanemdor’s latest stumble in Huntington’s disease has pushed Sage Therapeutics to pull the plug on the NMDA receptor modulator.
November 20, 2024
·
2 min read
·
Tristan Manalac
Podcast
Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More
Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million in radiopharma while selling its consumer health unit; Novo Nordisk’s positive Rybelsus results in cardiovascular disease; and more.
October 23, 2024
·
1 min read
·
Heather McKenzie
Earnings
Sage Touts Q3 Zurzuvae Revenue Growth, Will Not Seek MDD Indication
On its third-quarter earnings call Tuesday, Sage highlighted the launch of its Biogen-partnered postpartum depression drug Zurzuvae but said it will stop pursuing approval for major depressive disorder, which the FDA previously denied.
October 30, 2024
·
2 min read
·
Heather McKenzie
Layoffs
Sage Therapeutics Will Lay Off 33% of Employees, Including Over Half of R&D
As part of a strategic reorganization intended in part to support the ongoing launch of its postpartum depression drug, Sage Therapeutics is cutting more than 165 employees.
October 17, 2024
·
2 min read
·
Angela Gabriel
1 of 19,856
Next
